文献速递泌尿男性生殖肿瘤

立体定向放疗替代全身治疗用于寡转移性肾细胞癌:单臂、单中心、可行性、2期试验

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2021-10-28

这项单臂、单中心、2期可行性试验在30例寡转移性肾细胞癌患者中评估序贯放疗推迟全身治疗的可行性与疗效。所有患者完成至少一轮放疗且计划外中断<7天,中位无进展生存期22.7个月(95%CI 10.4-未达到),1年无进展生存率64%(95%CI 48-85)。3例(10%)发生严重不良事件,无治疗相关死亡。

要点

  • 30例寡转移性肾细胞癌患者接受立体定向体部放疗或大分割调强放疗,均完成至少一轮放疗且计划外中断<7天。
  • 中位随访17.5个月(IQR 13.2-24.6),中位无进展生存期22.7个月(95%CI 10.4-未达到),1年无进展生存率64%(95%CI 48-85)。
  • 3例(10%)发生严重不良事件:2例3级(背痛和肌无力),1例4级(高血糖),无治疗相关死亡。

核心结论

  • 序贯放疗可能有助于推迟寡转移性肾细胞癌患者启动全身治疗,并可能使部分患者获得持续的全身治疗间歇。

研究设计与样本

  • 单臂、2期、可行性试验,在美国休斯顿MD Anderson癌症中心单中心开展,2018年7月13日至2020年9月18日入组30例患者(6例[20%]女性)。
  • 入组条件:年龄≥18岁,转移病灶≤5个,ECOG体能状态0-2分,既往全身治疗不超过1种(若已停止至少1个月),不限肾细胞癌组织学类型。
  • 干预:对所有病灶行立体定向体部放疗(定义为≤5次分割且每次≥7 Gy),并维持不进行全身治疗;当病灶位置无法安全行立体定向体部放疗时,采用大分割调强放疗方案(60-70 Gy分10次或52.5-67.5 Gy分15次);允许对后续进展部位追加放疗。
  • 共同主要终点为可行性(定义为所有计划放疗完成且计划外中断<7天)和无进展生存期;疗效分析采用意向性治疗人群,安全性分析采用实际治疗人群。
  • 另启动第二队列评估序贯单纯立体定向体部放疗在低体积转移性疾病患者中的可行性,将另行报告;试验注册号ClinicalTrials.gov NCT03575611。

主要发现

  • 全部30例患者均为透明细胞组织学,入组前均接受过肾切除术。
  • 所有患者完成至少一轮放疗且计划外中断<7天。
  • 中位随访17.5个月(IQR 13.2-24.6),中位无进展生存期22.7个月(95%CI 10.4-未达到),1年无进展生存率64%(95%CI 48-85)。
  • 3例(10%)患者发生严重不良事件:2例3级(背痛和肌无力),1例4级(高血糖);无治疗相关死亡。

关键数值与推荐

  • 可行性定义:所有计划放疗完成且计划外中断<7天,本试验全部30例患者均达到。
  • 立体定向体部放疗定义:≤5次分割且每次≥7 Gy。
  • 大分割调强放疗方案:60-70 Gy分10次或52.5-67.5 Gy分15次。

临床怎么用

  • 作者认为,序贯放疗可能有助于推迟寡转移性肾细胞癌患者启动全身治疗,并可能使部分患者获得持续的全身治疗间歇。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of radiotherapy in metastatic renal cell carcinoma is controversial. We prospectively tested the feasibility and efficacy of radiotherapy to defer systemic therapy for patients with oligometastatic renal cell carcinoma. METHODS: This single-arm, phase 2, feasibility trial was done at one centre in the USA (The MD Anderson Cancer Center, Houston, TX, USA). Patients (aged ≥18 years) with five or fewer metastatic lesions, an Eastern Cooperative Oncology Group status of 0-2, and no more than one previous systemic therapy (if this therapy was stopped at least 1 month before enrolment) without limitations on renal cell carcinoma histology were eligible for inclusion. Patients were treated with stereotactic body radiotherapy (defined as ≤5 fractions with ≥7 Gy per fraction) to all lesions and maintained off systemic therapy. When lesion location precluded safe stereotactic body radiotherapy, patients were treated with hypofractionated intensity-modulated radiotherapy regimes consisting of 60-70 Gy in ten fractions or 52·5-67·5 Gy in 15 fractions. Additional rounds of radiotherapy were allowed to treat subsequent sites of progression. Co-primary endpoints were feasibility (defined as all planned radiotherapy completed with <7 days unplanned breaks) and progression-free survival. All efficacy analyses were intention-to-treat. Safety was analysed in the as-treated population. A second cohort, with the aim of assessing the feasibility of sequential stereotactic body radiotherapy alone in patients with low-volume metastatic disease, was initiated and will be reported separately. This study is registered with ClinicalTrials.gov, NCT03575611. FINDINGS: 30 patients (six [20%] women) were enrolled from July 13, 2018, to Sept 18, 2020. All patients had clear cell histology and had a nephrectomy before enrolment. All patients completed at least one round of radiotherapy with less than 7 days of unplanned breaks. At a median follow-up of 17·5 months (IQR 13·2-24·6), median progression-free survival was 22·7 months (95% CI 10·4-not reached; 1-year progression-free survival 64% [95% CI 48-85]). Three (10%) patients had severe adverse events: two grade 3 (back pain and muscle weakness) and one grade 4 (hyperglycaemia) adverse events were observed. There were no treatment-related deaths. INTERPRETATION: Sequential radiotherapy might facilitate deferral of systemic therapy initiation and could allow sustained systemic therapy breaks for select patients with oligometastatic renal cell carcinoma. FUNDING: Anna Fuller Foundation, the Cancer Prevention and Research Institute of Texas (CPRIT), and the National Cancer Institute.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Tang C, Msaouel P, Hara K, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021. PMID: 34717797. doi:10.1016/S1470-2045(21)00528-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。